

National Stock Exchange of India Circular

Department: LISTING	
Download Ref No: NSE/CML/76798	Date: October 08, 2026
Circular Ref. No: 1821/2026	

To All Members,

Sub: Trading of Rights Entitlements pursuant to Rights Issue of Natco Pharma Limited

In pursuance of Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations Part A, it is hereby notified that the list of securities further admitted to dealings on the National Stock Exchange (Capital Market segment) with effect from October 12, 2026 along with the designated security codes thereof shall be as specified in the Annexure.

In pursuance of Regulation 2.5.5 of the National Stock Exchange (Capital Market) Trading Regulations Part A, it is hereby notified that the respective lot sizes in respect of securities above shall be as specified in Annexure.

For the purpose of trading on the system, the security shall be identified only by its designated codes and trading in such securities shall be in such lot sizes as specified in Annexure.

Trading members shall inform all its clients about the commencement of trading in REs mentioning the ISIN of the RE and that the same shall not be mistaken for ordinary shares of the concerned company.

Trading members shall include a disclaimer prominently in the contract notes / bill containing purchase of REs informing the Clients that the purchase of REs only gives them the right to participate in the ongoing Rights Issue of the concerned company by making an application with requisite application money or renounce the REs before the issue closes. REs which are neither subscribed by making an application with requisite application money nor renounced, on or before the Issue Closing Date shall lapse and shall be extinguished after the Issue Closing Date.

This circular shall be effective from October 12, 2026.

For and on behalf of
National Stock Exchange of India Limited

Srishti Soni
Manager

Annexure

Symbol	NATCO-RE
Name of the Company	Natco Pharma Limited
Display name	Natco Pharma Limited-RE
Series	BE
ISIN	INE987B20018
Security Description	Trading of Rights Entitlement pursuant to Rights Issue
No. of Rights Entitlements	17058082
Trading period for Renunciation of Rights Entitlements (REs)	October 12, 2026 to October 16, 2026
Date of Suspension	October 19, 2026
Market lot	1

The Rights Entitlements of Natco Pharma Limited (Symbol: NATCO-RE) shall be traded in the Trade to Trade segment in compulsory demat for all investors.